ReviewCardiovascular and interventional radiology2026
Real-World Evidence: Better than Nothing or the Future? A Perspective on Clinical Evidence Generation in Interventional Oncology.
Review in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Real-World Imaging Data: Opportunities and Challenges.JMIR medical informatics · 2026Article
- Tumor ablation: emerging uses, challenges, and strategic implementation. A green paper by the Network of Expertise in Cancer (JANE-2), High Tech Medical Resources, network on Physical Methods of Tumor Ablation.Radiology and oncology · 2026Review
- Innovative strategies for early detection of cardiotoxicity: artificial intelligence and multi-modality collaborative models.Journal of thrombosis and thrombolysis · 2026Review
- Clinical Trials in Interventional Oncology: A Field Growing Up Fast.Cardiovascular and interventional radiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Randomised controlled trials (RCTs) have traditionally been regarded as the gold standard in evidence-based medicine, providing a high level of evidence. However, mounting complexities, ranging from ethical issues and logistical barriers to rapid technological evolutions, have sparked interest in alternative or complementary evidence-generation methods. Real-world evidence (RWE) from large, well-designed research projects is increasingly viewed as powerful tools. Although RWE is sometimes perceived as "less robust" compared to RCTs due to potential biases, recent advances in study design, data capture, and analytical frameworks have highlighted its potential for shaping clinical practice and informing regulatory decisions. This article discusses the benefits and challenges of RWE within interventional oncology and explores whether it is merely "better than nothing" or indeed represents a key pillar of the future of clinical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.